Sample Pharmacy
Hazardous Drug List and AoR Designation Table Template

Packaging is how it is supplied: UD = unit dose SD = single-dose vial MD = multidose package (vial or bulk tablet bottle)
NIOSH type of HD: **1** = NIOSH Table 1 **2** = NIOSH Table 2
Type of hazard: Describe why drug presents a hazard (see MSHIs; package inserts, manufacturer warnings, other credible medical publications)
Alternative containment strategies: See F-701.b and Manufacturer's Safe Handling (if any); Information in NIOSH Managing Hazardous Drug Exposures: Information for Healthcare Settings

Date added	Drug name and type of formulation (capsule, tablet, solution, powder, etc.)	How supplied or packaging	NIOSH Table	Type of hazard activities that pose a risk to employees	Alternative containment strategy and work practices	
					Category/Name from F-603.a	Additional comments (see F-603.a)
1/27/2025	Cyclophosphamide powder for solution	SD	1	IARC Group 1 carcinogen; NTP; FDA Pregnancy Category D	A	Follow all requirements of USP 800
1/27/2025	Mercaptopurine tablets	MD	1	FDA Pregnancy Category D	A	Split tablets and package in unit-dose tablet containment packaging system Follow all requirements of USP 800
1/27/2025	Methotrexate injectable solution	SD	1	FDA Pregnancy Category X	A	Follow all requirements of USP 800 If dispensing single-dose vial for ambulatory care, follow Category D
1/27/2025	Methotrexate tablets	MD	1	FDA Pregnancy Category X	A	Split tablets and package in unit-dose tablet containment packaging system Follow all requirements of USP 800
1/27/2025	Azathioprine tablets	UD	1	IARC Group 1 FDA Pregnancy Cat D	B	If splitting or repackaging tablets, follow Category B
1/27/2025	Azathioprine suspension	MD	1	IARC Group 1 FDA Pregnancy Cat D	B	If compounding azathioprine suspension, follow Category B
1/27/2025	Abacavir tablets	UD	2	FDA Pregnancy Cat C (no definitive human risk but was a risk in animals) Minimal exposure risk.	C	If repackaging or splitting abacavir tablets, follow Category C
1/27/2025	Carbamazepine controlled-release tablets (Tegretol XR)	UD	2	Black Box warning for aplastic anemia; congenital malformations in offspring of mothers who took drug; rapid transplacental passage; FDA Pregnancy Cat D* Risk primarily from ingestion/dust exposure, therefore, any manipulation (crushing of tablet) would release tablet dust (powder)	C	Repackaging carbamazepine controlled-release tablets follows Category C **Tablets may NOT be split or crushed.**

Example of Form Use Only!
Information may not be accurate for your Pharmacy.
For demonstration of for use only!

© 2025 TRC is a registered trademark of Therapeutic Research Center. TRC and all associated names and service marks including TRC are restricted and reserved for Therapeutic Research Center use. TRCHealthcare.com

Sample Pharmacy
Hazardous Drug List and AoR Designation Table Template

Packaging is how it is supplied: UD = unit dose SD = single-dose vial MD = multidose package (vial or bulk tablet bottle)
NIOSH type of HD: **1** = NIOSH Table 1 **2** = NIOSH Table 2
Type of hazard: Describe why drug presents a hazard (see MSHIs; package inserts, manufacturer warnings, other credible medical publications)
Alternative containment strategies: See F-701.b and Manufacturer's Safe Handling (if any); Information in NIOSH Managing Hazardous Drug Exposures: Information for Healthcare Settings

Date added	Drug name and type of formulation (capsule, tablet, solution, powder, etc.)	How supplied or packaging	NIOSH Table	Type of hazard activities that pose a risk to employees	Alternative containment strategy and work practices	
					Category/Name from F-603.a	Additional comments (see F-603.a)
10/28/24	Carbamazepine controlled-release tablets (Tegretol XR)	MD	2	Black Box warning for aplastic anemia; congenital malformations in offspring of mothers who took drug; rapid transplacental passage; FDA Pregnancy Cat D* Risk primarily from ingestion/dust exposure, therefore, any manipulation (crushing of tablet) would release tablet dust (powder)	D	If unit dose product is unavailable, follow Category C **Tablets may NOT be split or crushed.**
1/27/2025	Cyclosporine capsule	UD	2	IARC Group 1 carcinogen FDA pregnancy Cat C (no well-controlled studies in humans, but animal studies have shown adverse fetal effects).	D	Purchase unit-dose product. **Tablets may NOT be split or crushed.**
1/27/2025	Mercaptopurine tablets	UD	1	FDA Pregnancy Category D	D	Purchase unit-dose product. If splitting tablets, follow Category A
1/27/2025	Methotrexate tablets	UD	1	FDA Pregnancy Category X	D	Purchase unit-dose product. If splitting tablets, follow Category A
1/27/2025	Oxytocin injectable solution	SD	2	FDA Pregnancy Cat C Risk to women in the 3rd trimester	E	Women in 3rd trimester, follow Category E
1/27/2025	Fosphenytoin injectable solution	SD	2	Metabolized to phenytoin; FDA Pregnancy Cat D; Risk to women in 2nd trimester or beyond	E	Women in 2nd trimester and beyond, follow Category E

Example of Form Use Only!
Information may not be accurate for your Pharmacy.
For demonstration or for use only!

Date list and contents last reviewed:_____ Name of person reviewing/updating:_____

Approved by HD designated person:_____ Date:_____

© 2025 TRC is a registered trademark of Therapeutic Research Center. TRC and all associated names and service marks including TRC are restricted and reserved for Therapeutic Research Center use. TRCHealthcare.com